Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity.
作者信息
Ray Arghya, Du Ting, Song Yan, Buhrlage Sara J, Chauhan Dharminder, Anderson Kenneth C
机构信息
The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
出版信息
Leukemia. 2021 Aug;35(8):2435-2438. doi: 10.1038/s41375-021-01129-0. Epub 2021 Jan 24.
Abstract
摘要
相似文献
1
Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity.靶向浆细胞样树突状细胞中的泛素特异性蛋白酶-7可触发抗骨髓瘤免疫。
Leukemia. 2021 Aug;35(8):2435-2438. doi: 10.1038/s41375-021-01129-0. Epub 2021 Jan 24.
2
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.靶向浆细胞样树突状细胞与T细胞、自然杀伤细胞和多发性骨髓瘤细胞相互作用中的PD1-PDL1免疫检查点。
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.
3
Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma.自然杀伤细胞刺激树突状细胞诱导多发性骨髓瘤患者骨髓瘤特异性细胞毒性 T 淋巴细胞反应。
Leuk Res. 2011 Sep;35(9):1241-7. doi: 10.1016/j.leukres.2011.03.032. Epub 2011 May 25.
4
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.α-烯醇化酶（ENO1）作为多发性骨髓瘤新型免疫代谢靶点的临床前验证。
Oncogene. 2020 Mar;39(13):2786-2796. doi: 10.1038/s41388-020-1172-0. Epub 2020 Feb 5.
5
Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.浆细胞样树突状细胞中泛素受体Rpn13的阻断引发抗骨髓瘤免疫。
Blood Cancer J. 2019 Aug 12;9(8):64. doi: 10.1038/s41408-019-0224-6.
6
Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70.膜结合 HSP70 工程骨髓瘤细胞衍生的外泌体比表达细胞质 HSP70 的热休克肿瘤细胞释放的外泌体更能刺激有效的 CD8(+)CTL 和 NK 介导的抗肿瘤免疫。
J Cell Mol Med. 2010 Nov;14(11):2655-66. doi: 10.1111/j.1582-4934.2009.00851.x.
7
Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies.用负载有 MUC1 和 hTERT 驱动的九肽或骨髓瘤细胞凋亡小体的树突状细胞生成骨髓瘤特异性 T 细胞。
Neoplasma. 2010;57(5):455-64. doi: 10.4149/neo_2010_05_455.
8
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.树突状细胞与泊马度胺协同抗骨髓瘤作用的小鼠骨髓瘤模型研究。
Front Immunol. 2018 Aug 3;9:1798. doi: 10.3389/fimmu.2018.01798. eCollection 2018.
9
Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.靶向热休克蛋白用于多发性骨髓瘤的免疫治疗：利用负载肿瘤源性gp96的树突状细胞产生骨髓瘤特异性细胞毒性T淋巴细胞
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8808-15. doi: 10.1158/1078-0432.CCR-05-1553.
引用本文的文献
1
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.鉴定和验证外核苷酸酶为多发性骨髓瘤的免疫治疗靶点。
Blood Cancer J. 2022 Apr 1;12(4):50. doi: 10.1038/s41408-022-00635-3.
本文引用的文献
1
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.选择性 USP7 抑制通过 p53 依赖性机制引发癌细胞杀伤。
Sci Rep. 2020 Mar 24;10(1):5324. doi: 10.1038/s41598-020-62076-x.
2
Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance.抑制 Nr4a 受体通过打破 Treg 介导的免疫耐受增强抗肿瘤免疫。
Cancer Res. 2018 Jun 1;78(11):3027-3040. doi: 10.1158/0008-5472.CAN-17-3102. Epub 2018 Mar 20.
3
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.在新药时代恢复自然杀伤细胞对多发性骨髓瘤的免疫作用
Front Immunol. 2017 Nov 7;8:1444. doi: 10.3389/fimmu.2017.01444. eCollection 2017.
4
Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer.调节性T细胞与肿瘤相关树突状细胞之间的串扰削弱了胰腺癌的抗肿瘤免疫。
Cell Rep. 2017 Jul 18;20(3):558-571. doi: 10.1016/j.celrep.2017.06.062.
5
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.19S蛋白酶体亚基的抑制标志着多种癌症中一种改变的细胞状态的出现。
Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):382-387. doi: 10.1073/pnas.1619067114. Epub 2016 Dec 27.
6
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.靶向浆细胞样树突状细胞与T细胞、自然杀伤细胞和多发性骨髓瘤细胞相互作用中的PD1-PDL1免疫检查点。
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.
7
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.一种新型 TLR-9 激动剂 C792 抑制浆细胞样树突状细胞诱导的骨髓瘤细胞生长并增强硼替佐米的细胞毒性。
Leukemia. 2014 Aug;28(8):1716-24. doi: 10.1038/leu.2014.46. Epub 2014 Jan 30.
8
The resistance mechanisms of proteasome inhibitor bortezomib.蛋白酶体抑制剂硼替佐米的耐药机制。
Biomark Res. 2013 Mar 1;1(1):13. doi: 10.1186/2050-7771-1-13.
9
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.蛋白酶体β5 亚基突变导致硼替佐米结合能力受损是白血病细胞硼替佐米耐药的基础。
Leukemia. 2012 Apr;26(4):757-68. doi: 10.1038/leu.2011.256. Epub 2011 Sep 23.
10
Regulatory T cells and Foxp3.调节性 T 细胞和 Foxp3。
Immunol Rev. 2011 May;241(1):260-8. doi: 10.1111/j.1600-065X.2011.01018.x.
Zotero 插件